Cardiovascular health, heart failure, atherosclerosis, and cardiac research
460 articles
A mass spectrometry apolipoprotein panel predicts cardiovascular events and identifies who gains the most from PCSK9 inhibitor therapy.
A 94,000-person study finds high remnant cholesterol raises heart disease risk 45% — yet triggers far less statin prescribing than high LDL.
A newly discovered mitochondrial protein boosts cardiac glucose burning and dramatically reduces heart injury after ischemia-reperfusion.
A major RCT of 1,840 ICU patients finds limiting oxygen after cardiac arrest does not improve survival or functional outcomes.
A mitochondrial enzyme found upregulated in pulmonary hypertension patients triggers vascular damage through a noncanonical mechanism — and a known drug can block it.
New analysis of 3,698 post-MI patients shows elevated heart rate predicts worse outcomes, and stopping beta-blockers raises HR by 10–13 bpm.
A new study finds elevated apolipoprotein B strongly predicts reduced myocardial flow reserve, deepening its role in cardiovascular risk.
A 2025 review maps the key genetic mutations, polygenic risk scores, and emerging therapies reshaping early-onset CVD prevention.
New research in Circulation explores how cardiac biomarkers may serve as early predictors of skeletal muscle deterioration.
Experts weigh in on whether right ventricular-pulmonary arterial coupling during exercise predicts outcomes in mitral regurgitation.
A completed Phase 3 RCT examines whether weekly semaglutide injections improve symptoms and body weight in heart failure patients with obesity.
A Phase 3 trial examines whether bococizumab slashes LDL in statin-treated patients at elevated cardiovascular risk.
